Matrix metalloproteinase-26 (Matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer
Authors:
- G.D. NorataG.D. Norata
- H. DomanskiHDH. Domanski
- C. AnderssonCAC. Andersson
- S. HanssonSHS. Hansson
- P. ErikssonPEP. Eriksson
- B. CasslénBCB. Casslén
- 1 September 2004
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (3) , 661-670
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Strategies for MMP inhibition in cancer: innovations for the post-trial eraNature Reviews Cancer, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Matrix metalloproteinases: they're not just for matrix anymore!Current Opinion in Cell Biology, 2001
- Matrix Metalloproteinases: Biologic Activity and Clinical ImplicationsJournal of Clinical Oncology, 2000
- The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary CarcinogenesisCell, 1999
- Changing views of the role of matrix metalloproteinases in metastasisJNCI: Journal of the National Cancer Institute, 1997
- Matrilysin expression in human prostate carcinomaMolecular Carcinogenesis, 1996
- Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factorArchives of Biochemistry and Biophysics, 1991
- A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomasNature, 1990
- Metastatic potential correlates with enzymatic degradation of basement membrane collagenNature, 1980